Peter Hamilton outlined his intention to make a special clinical study of the problems of liver disease in haemophiliacs Read more about Peter Hamilton outlined his intention to make a special clinical study of the problems of liver disease in haemophiliacs
In her statement, Anne Kirkman Collins stated that the Newcastle Haemophilia Centre preferred commercial Factor VIII product because: it was more easily soluble, some patients had allergic reactions to NHS Factor VIII and the presentation of commercial product was more appealing to the centre. Read more about In her statement, Anne Kirkman Collins stated that the Newcastle Haemophilia Centre preferred commercial Factor VIII product because: it was more easily soluble, some patients had allergic reactions to NHS Factor VIII and the presentation of commercial product was more appealing to the centre.
It was clear, from a letter written by Dr Jones, that commercial concentrates were considered to be preferable for home therapy for reasons including "size of bottle, volume of fluid required for reconstitution, time of reconstitution, viscosity". Read more about It was clear, from a letter written by Dr Jones, that commercial concentrates were considered to be preferable for home therapy for reasons including "size of bottle, volume of fluid required for reconstitution, time of reconstitution, viscosity".
It was reported that at the Newcasle Haemophilia centre approximately 180,000 units of commercial concentrate had been bought in the past year to make up "the deficit in BTS supplied VIII products for in-patient use" within the Northern Regional Haemophilia Service. Read more about It was reported that at the Newcasle Haemophilia centre approximately 180,000 units of commercial concentrate had been bought in the past year to make up "the deficit in BTS supplied VIII products for in-patient use" within the Northern Regional Haemophilia Service.
The individual records enclosed with the 1979 return for the Newcastle Haemophilia Centre demonstrated that a number of individuals were treated with multiple products rather than kept on a single product. Read more about The individual records enclosed with the 1979 return for the Newcastle Haemophilia Centre demonstrated that a number of individuals were treated with multiple products rather than kept on a single product.
The annual retruns for Newcastle Haemophilia Centre recorded that 1978 Hemofil, Factorate and Koate were all in use, along with NHS concentrate. Read more about The annual retruns for Newcastle Haemophilia Centre recorded that 1978 Hemofil, Factorate and Koate were all in use, along with NHS concentrate.
The 1977 Newcastle Haemophilia Centre annual return recorded a very substantial increase in the use of Hemofil (2.3 million units, compared to 1.6 million units of NHS product). Read more about The 1977 Newcastle Haemophilia Centre annual return recorded a very substantial increase in the use of Hemofil (2.3 million units, compared to 1.6 million units of NHS product).
The Newcastle Haemophilia Centre annual returns from 1976 to 1979 recorded that Hemofil was the main product used for the treatment of Haemophilia A Read more about The Newcastle Haemophilia Centre annual returns from 1976 to 1979 recorded that Hemofil was the main product used for the treatment of Haemophilia A
By 1975, the use of commercial concentrate in the Northern Region had rapidly increased to 972,000 units; and by 1976, a great deal more commercial concentrate (1,649,240 units) was used than cryoprecipitate (676,050 units) and NHS concentrate (82,800 units) put together. Read more about By 1975, the use of commercial concentrate in the Northern Region had rapidly increased to 972,000 units; and by 1976, a great deal more commercial concentrate (1,649,240 units) was used than cryoprecipitate (676,050 units) and NHS concentrate (82,800 units) put together.
Dr Jones explained at the 3rd European Regional Congress of the Federation of Haemophilia in London that his policy was to treat under 6s with domestic cryoprecipitate while those above were treated with factor concentrates. Read more about Dr Jones explained at the 3rd European Regional Congress of the Federation of Haemophilia in London that his policy was to treat under 6s with domestic cryoprecipitate while those above were treated with factor concentrates.